Overview

A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Collaborator:
Mediscience Planning, Inc.
Treatments:
Firuglipel
Sitagliptin Phosphate